OrthoLogic Rehab Divestiture Will Fund Chrysalin Osteobiologics Development
This article was originally published in The Gray Sheet
Executive Summary
OrthoLogic is planning to divest its $60 mil. orthopedic rehabilitation device business and use the proceeds for further development of the osteobiologic product Chrysalin, and to expand the company's remaining fracture healing and spinal repair business, including possible acquisitions.